Cara Therapeutics, Inc. (CARA): Price and Financial Metrics


Cara Therapeutics, Inc. (CARA): $13.22

0.52 (+4.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CARA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

CARA POWR Grades


  • Value is the dimension where CARA ranks best; there it ranks ahead of 88.6% of US stocks.
  • The strongest trend for CARA is in Growth, which has been heading down over the past 52 weeks.
  • CARA's current lowest rank is in the Momentum metric (where it is better than 9.55% of US stocks).

CARA Stock Summary

  • The ratio of debt to operating expenses for Cara Therapeutics Inc is higher than it is for about just 8.42% of US stocks.
  • CARA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.97% of US stocks.
  • As for revenue growth, note that CARA's revenue has grown 413.22% over the past 12 months; that beats the revenue growth of 98.09% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cara Therapeutics Inc are CNCE, RCUS, ANAB, ALPN, and DTIL.
  • Visit CARA's SEC page to see the company's official filings. To visit the company's web site, go to www.caratherapeutics.com.

CARA Valuation Summary

  • In comparison to the median Healthcare stock, CARA's price/earnings ratio is 159.18% higher, now standing at 94.6.
  • CARA's EV/EBIT ratio has moved up 162.9 over the prior 92 months.
  • CARA's price/sales ratio has moved down 17.2 over the prior 92 months.

Below are key valuation metrics over time for CARA.

Stock Date P/S P/B P/E EV/EBIT
CARA 2021-08-31 6.4 3.9 94.6 96.9
CARA 2021-08-30 6.0 3.7 88.9 91.0
CARA 2021-08-27 5.9 3.6 87.4 89.4
CARA 2021-08-26 5.5 3.4 81.9 83.6
CARA 2021-08-25 5.8 3.5 85.6 87.4
CARA 2021-08-24 6.0 3.7 89.2 91.3

CARA Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at -360.31%.
  • Its 5 year revenue growth rate is now at 520.48%.
  • Its 5 year net cashflow from operations growth rate is now at -458.72%.
Over the past 49 months, CARA's revenue has gone up $122,379,000.

The table below shows CARA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 123.29 15.742 8.354
2021-03-31 128.924 9.095 14.031
2020-12-31 135.082 -5.487 8.41
2020-09-30 27.504 -118.741 -99.11
2020-06-30 24.023 -122.758 -115.443
2020-03-31 23.597 -120.002 -113.335

CARA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CARA has a Quality Grade of C, ranking ahead of 33.63% of graded US stocks.
  • CARA's asset turnover comes in at 0.554 -- ranking 71st of 681 Pharmaceutical Products stocks.
  • APLS, AUPH, and FENC are the stocks whose asset turnover ratios are most correlated with CARA.

The table below shows CARA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.554 1 0.046
2021-03-31 0.616 1 0.091
2020-12-31 0.690 1 0.059
2020-09-30 0.148 1 -0.840
2020-06-30 0.112 1 -0.773
2020-03-31 0.112 1 -0.754

CARA Price Target

For more insight on analysts targets of CARA, see our CARA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.33 Average Broker Recommendation 1.44 (Moderate Buy)

CARA Stock Price Chart Interactive Chart >

Price chart for CARA

CARA Price/Volume Stats

Current price $13.22 52-week high $29.65
Prev. close $12.70 52-week low $11.22
Day low $12.68 Volume 437,100
Day high $13.25 Avg. volume 1,067,818
50-day MA $14.43 Dividend yield N/A
200-day MA $16.57 Market Cap 662.19M

Cara Therapeutics, Inc. (CARA) Company Bio


Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The company was founded in 2004 and is based in Shelton, Connecticut.


CARA Latest News Stream


Event/Time News Detail
Loading, please wait...

CARA Latest Social Stream


Loading social stream, please wait...

View Full CARA Social Stream

Latest CARA News From Around the Web

Below are the latest news stories about Cara Therapeutics Inc that investors may wish to consider to help them evaluate CARA as an investment opportunity.

Are Cara Therapeutics, Inc.'s (NASDAQ:CARA) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Cara Therapeutics (NASDAQ:CARA) has had a rough month with its share price down 8.8%. It seems that the market might...

Yahoo | October 15, 2021

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. Results were presented by Brian Kim, MD, Associat

Yahoo | October 4, 2021

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presentedSTAMFORD, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that results from the KARE Phase 2 clinical trial of Oral KORSUVA™ (difelik

Yahoo | September 29, 2021

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.

Yahoo | September 24, 2021

Cara Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.

Yahoo | September 24, 2021

Read More 'CARA' Stories Here

CARA Price Returns

1-mo -17.01%
3-mo 9.35%
6-mo -6.04%
1-year -5.10%
3-year -29.19%
5-year 88.59%
YTD -12.62%
2020 -6.08%
2019 23.92%
2018 6.21%
2017 31.75%
2016 -44.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8514 seconds.